

IN THE CLAIMS:

*22 Apr 17* (Amended) An agonist antibody which specifically binds to the extracellular domain of WSX receptor comprising the extracellular domain sequence within SEQ ID NO:2.

*23 Apr 17* 3. (Amended) The antibody of claim 2 which specifically binds to and activates human WSX receptor variant 13.2 (SEQ ID NO:2).

*24 Apr 17* 10. (Amended) The antibody of claim 1 which has biological characteristics of antibody 2D7 (ATCC Accession Number HB-12249).

*25* 13. (Amended) The antibody of claim 1 which has the biological characteristics of antibody 1G4 (ATCC Accession Number HB-12243).

*26* 16. (Amended) The antibody of claim 1 which has the biological characteristics of antibody 1E11 (ATCC Accession Number HB-12248).

*27* 19. (Amended) The antibody of claim 1 which has the biological characteristics of antibody 1C11 (ATCC Accession Number HB-12250).

Please cancel claims 34-39, without prejudice to filing continuing application(s) directed thereto.

Please add the following claims:

*28* --40. The antibody of claim 1 which mimics a biological property of OB protein.

41. The antibody of claim 1 which stimulates proliferation or differentiation of a cell which expresses the WSX receptor.

42. The antibody of claim 1 which decreases body weight or fat-depot weight or food intake in an obese mammal.--